echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Dinghang pharmaceutical announced the strategic cooperation of global clinical research on gastric cancer combined with MSD

    Dinghang pharmaceutical announced the strategic cooperation of global clinical research on gastric cancer combined with MSD

    • Last Update: 2019-08-15
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    August 14, 2019 / AP / -- oncologie, a global leader in tumor immunotherapy, announced a clinical cooperation agreement with MSD (known as Merck Merck in the United States and Canada) The two sides will jointly evaluate bavituximab, a new drug under development in dinghang, which specifically blocks phosphatidylserine (PS), The efficacy of the combination of an innovative monoclonal antibody drug with the anti PD-1 drug keytruda ® (pabolizumab) of methadone in the treatment of advanced gastric cancer and gastroesophageal cancer According to the agreement, dinghang pharmaceutical will carry out a single arm, open label global clinical phase 2 study to determine the efficacy and safety of bavituximab combined with keytruda ® in the treatment of patients with advanced gastric cancer and gastroesophageal cancer, who have previously received at least one first-line treatment plan and have no effect The clinical study plans to recruit about 80 patients in the United States, the United Kingdom, South Korea and Taiwan, and patient recruitment is expected to start in the second half of 2019 "Gastric cancer is a common and urgent malignant tumor in many regions of the world We hope to learn about the clinical effectiveness of bavituximab and keytruda ® in jointly treating this refractory cancer through this research cooperation," Laura Benjamin, co founder and CEO of dinghang pharmaceutical "This cooperation also reflects the common commitment of both sides to improve and improve the lives of cancer patients," said Dr Keytruda ® is a registered trademark of Merck sharp & Dohme Corp Merck & Co., Inc is a subsidiary of Merck & Co., Inc in kennarworth, New Jersey Bavituximab is an innovative chimeric monoclonal antibody drug targeting phosphatidylserine (PS) in clinical stage Bavituximab is believed to reverse PS mediated immunosuppression by blocking PS binding to its receptor The results show that the antibody targeting PS has the function of activating the immune cells in tumor, and it can induce many reactions such as human immune activation and anti-tumor immune response By reversing the mechanism of immunosuppression, PS antibody may help other cancer therapies to attack tumors more effectively and unrestricted It is worth mentioning that bavituximab has shown good controllable safety and tolerance in a number of clinical trials conducted so far, which will enable it to be effectively combined with other therapies About dinghang medicine, founded in 2018, dinghang medicine is committed to the discovery and development of new drugs for tumor immunotherapy With the academic expertise and rich business experience of the founding team, the company has established a group of new drug candidates with global intellectual property rights and high differentiation The company's product candidates include the first in class drugs with new mechanism, the best in class drugs for improving and upgrading existing drugs, and the accompanying diagnosis platform for tumor immunotherapy Two of them are in the clinical stage (drug B and drug L) The company is currently conducting three clinical trials at the same time Dinghang pharmaceutical company is headquartered in Boston and has clinical executive teams in Boston and Shanghai Source: dinghang pharmaceutical
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.